Nabriva Therapeutics AG (NBRV) Lifted to Hold at Zacks Investment Research

Nabriva Therapeutics AG (NASDAQ:NBRV) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued to investors on Tuesday.

According to Zacks, “Nabriva Therapeutics AG is a biopharmaceutical company. The Company is involved in the research and development of novel anti-infective agents to treat serious infections, which focus on the pleuromutilin class of antibiotics. Its product candidate consists of BC-3781, developed for the treatment of serious skin infections and bacterial pneumonia caused by MRSA and other drug resistant bacteria; BC-7013, a topical pleuromutilin antibiotic which are in different clinical trial. Nabriva Therapeutics AG is based in Vienna, Austria. “

Several other research firms have also recently commented on NBRV. Cantor Fitzgerald restated an “overweight” rating on shares of Nabriva Therapeutics AG in a research report on Friday, June 23rd. Needham & Company LLC reiterated a “buy” rating and issued a $15.00 price objective on shares of Nabriva Therapeutics AG in a report on Monday, March 27th. HC Wainwright reiterated a “buy” rating and issued a $16.00 price objective on shares of Nabriva Therapeutics AG in a report on Friday, June 30th. ValuEngine upgraded shares of Nabriva Therapeutics AG from a “sell” rating to a “hold” rating in a report on Saturday, June 24th. Finally, Wedbush reiterated an “outperform” rating and issued a $13.00 price objective on shares of Nabriva Therapeutics AG in a report on Monday, May 15th. Two research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $15.29.

Shares of Nabriva Therapeutics AG (NASDAQ:NBRV) opened at 10.35 on Tuesday. The company has a 50-day moving average of $9.87 and a 200-day moving average of $9.52. The firm’s market cap is $28.16 million. Nabriva Therapeutics AG has a 12 month low of $3.52 and a 12 month high of $12.75.

COPYRIGHT VIOLATION WARNING: “Nabriva Therapeutics AG (NBRV) Lifted to Hold at Zacks Investment Research” was originally reported by Ticker Report and is the sole property of of Ticker Report. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of United States and international trademark and copyright legislation. The original version of this story can be accessed at https://www.tickerreport.com/banking-finance/2724547/nabriva-therapeutics-ag-nbrv-lifted-to-hold-at-zacks-investment-research.html.

In other Nabriva Therapeutics AG news, major shareholder Hbm Healthcare Investments (Ca sold 23,932 shares of the company’s stock in a transaction that occurred on Thursday, April 20th. The shares were sold at an average price of $11.11, for a total value of $265,884.52. Following the transaction, the insider now owns 2,624,633 shares in the company, valued at approximately $29,159,672.63. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director George Harrison Talbot sold 325 shares of the company’s stock in a transaction that occurred on Thursday, May 25th. The shares were sold at an average price of $100.56, for a total transaction of $32,682.00. Following the completion of the transaction, the director now owns 3,854 shares in the company, valued at approximately $387,558.24. The disclosure for this sale can be found here. In the last 90 days, insiders sold 126,778 shares of company stock valued at $1,453,057.

Several hedge funds and other institutional investors have recently made changes to their positions in NBRV. Wellington Management Group LLP raised its position in shares of Nabriva Therapeutics AG by 9.9% in the first quarter. Wellington Management Group LLP now owns 2,154,261 shares of the biotechnology company’s stock valued at $25,830,000 after buying an additional 193,951 shares during the period. Nationwide Fund Advisors acquired a new position in shares of Nabriva Therapeutics AG during the first quarter valued at approximately $2,074,000. Almanack Investment Partners LLC. acquired a new position in shares of Nabriva Therapeutics AG during the first quarter valued at approximately $1,870,000. Finally, Renaissance Technologies LLC acquired a new position in shares of Nabriva Therapeutics AG during the fourth quarter valued at approximately $103,000. Institutional investors own 56.73% of the company’s stock.

About Nabriva Therapeutics AG

Nabriva Therapeutics AG is an Austria-based clinical-stage biopharmaceutical company engaged in the research and development of antibiotics to treat infections. Its lead product candidate, lefamulin, is a pleuromutilin antibiotic for systemic administration in humans. The Company develops both intravenous (IV) and oral formulations of lefamulin for the treatment of community-acquired bacterial pneumonia (CABP).

Get a free copy of the Zacks research report on Nabriva Therapeutics AG (NBRV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Nabriva Therapeutics AG (NASDAQ:NBRV)

Receive News & Ratings for Nabriva Therapeutics AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics AG and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
Shares at Radius Jump as Bone Drug of Amgen Has Setback
Shares at Radius Jump as Bone Drug of Amgen Has Setback


Leave a Reply

© 2006-2017 Ticker Report. Google+.